Clinical trialPhase 2Terminated
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
- Outcome
- Stopped earlyExtreme toxicity of Pertuzumab and Erlotinib combination (Toxicity)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- March 2009
- Expected end
- May 2010
- Enrollment
- 4 participants
- Sites
- 1
- Primary outcomes
- Response Rate (RR) for All Patients Treated With This Strategy (Simon Design)
- Sponsor
- Other
- Results posted
- 2017-03-03
- Last update
- 3 March 2017
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who have stable disease or progressive disease at three months (Simon design).
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Response Rate (RR) for All Patients Treated With This Strategy (Simon Design) [CT scans are done every 4 cycles (every 12 wks)]. Count Of Participants, Participants. Pertuzumab and Erlotinib (n=4): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Toxicities Assessed by CTCAE Grading Criteria and Assigned Attributions Accordingly [AEs are assessed every cycle (every 3 wks)]. Count Of Participants, Participants. Pertuzumab and Erlotinib (n=4): 4.